MA-IBASIS
29.6.2021 08:02:06 CEST | Business Wire | Press release
iBASIS , the leading provider of communications solutions for operators and digital players worldwide, announced it will partner with SIPPIO , the largest, secure, Azure-based provider of voice-calling services for Microsoft Teams, globally. The relationship enables both companies to address the fast-growing global demand for unified communications and collaboration services with Cloud Numbering and International Voice Termination.
The seismic shift to all cloud-based communication platforms is exemplified by Microsoft Teams’ 145 million daily active users. As recently reported by Synergy Group Research , “Microsoft has become the second-largest Unified Communications-as-a-Service (UCaaS) provider in the world.” As usage increases, so does the demand for exponentially growing voice calling services.
iBASIS and SIPPIO are responding to this demand with iBASIS’ expansion of Cloud Numbering and International Voice Termination combined with SIPPIO’s fully automated, end-to-end cloud solution platform, delivering top-grade communications and carrier services and leveraging automation to eliminate the cost, complexity, and time of building direct routing as a ‘one-off.’ This ensures both reliability and redundancy on a global scale with the highest levels of security, compliance, and data privacy.
iBASIS provides SIPPIO with enhanced coverage in various hard-to-reach destinations across the globe. Recent examples of iBASIS’ strengths in addressing demand from key geographies include iBASIS’ partnership with China Telecom Europe , which enabled CTE to achieve instant traction by leveraging iBASIS Carrier Voice for Teamwork™ to provide European multinationals with full calling capabilities to their collaboration platforms.
“SIPPIO is an innovative cloud solution player forging new capabilities and commercialization opportunities for fully automated, cloud-based direct routing as a service,” says Edwin van Ierland , Chief Commercial Officer and Chief Operating Officer at iBASIS. “This relationship showcases how iBASIS’ Carrier Cloud Communications portfolio , global reach, scale, and independence are critical to the global requirements for cloud communications.”
“This is a pivotal moment in which the demand to shift voice calling to the same world as online meetings is a major market driver,” adds Dawn-Marie Elder, COO, SIPPIO. “Partnering with iBASIS extends SIPPIO’s global footprint, reinforcing our ability to provide operators with the highest quality, tier-1 voice capabilities and fastest time to market to bring these solutions to their enterprise customers.”
iBASIS Carrier Voice for Teamwork is part of iBASIS’ larger Carrier Cloud Communications portfolio that includes cloud numbering solutions, international numbers, global voice termination, and Communications Platform as a Service (CPaaS). iBASIS’ carrier-grade API marketplace includes a full CPaaS suite to meet the growing and urgent need for collaborative tools and applications – including solutions for iBASIS Carrier Voice for Teamwork™ , two-factor authentication, live support, and contact center services.
SIPPIO empowers channel partners and carriers with capabilities to capitalize on the demand for voice-enabled collaboration platforms like Microsoft Teams. By minimizing resource consumption from end to end, SIPPIO expands the universe of potential customers for partners, making it economically viable to pursue smaller companies as well as Fortune 500 enterprises.
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.
About SIPPIO
Headquartered in Annapolis, MD, SIPPIO is the largest platform provider to enable voice in Microsoft Teams. As a Co-Sell Preferred partner, SIPPIO provides partners and carriers with a fully automated, Azure native, end-to-end solution. Available globally with toll-free and emergency services, SIPPIO does not require any code, build, or maintenance. SIPPIO activates full calling capabilities in minutes and scales with business needs to enhance communications and collaboration to unify the modern workplace experience. Visit www.sippio.io for additional information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005768/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom